Free Trial

Septerna (SEPN) Competitors

Septerna logo
$16.06 +0.06 (+0.38%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$16.12 +0.06 (+0.40%)
As of 09/23/2025 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SEPN vs. CGON, MOR, HCM, RARE, OGN, ALVO, KNSA, IMVT, GMTX, and MLYS

Should you be buying Septerna stock or one of its competitors? The main competitors of Septerna include CG Oncology (CGON), MorphoSys (MOR), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Organon & Co. (OGN), Alvotech (ALVO), Kiniksa Pharmaceuticals International (KNSA), Immunovant (IMVT), Gemini Therapeutics (GMTX), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry.

Septerna vs. Its Competitors

Septerna (NASDAQ:SEPN) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Septerna currently has a consensus price target of $26.75, indicating a potential upside of 66.56%. CG Oncology has a consensus price target of $56.00, indicating a potential upside of 52.59%. Given Septerna's higher probable upside, research analysts plainly believe Septerna is more favorable than CG Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Septerna
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
CG Oncology
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.92

In the previous week, CG Oncology had 13 more articles in the media than Septerna. MarketBeat recorded 16 mentions for CG Oncology and 3 mentions for Septerna. Septerna's average media sentiment score of 0.63 beat CG Oncology's score of 0.53 indicating that Septerna is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Septerna
0 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CG Oncology
7 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Septerna has higher earnings, but lower revenue than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Septerna, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Septerna$1.08M662.92-$71.80M-$10.09-1.59
CG Oncology$1.14M2,454.71-$88.04M-$1.77-20.73

26.6% of CG Oncology shares are owned by institutional investors. 4.3% of Septerna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Septerna has a net margin of -12,053.03% compared to CG Oncology's net margin of -15,945.17%. CG Oncology's return on equity of -19.37% beat Septerna's return on equity.

Company Net Margins Return on Equity Return on Assets
Septerna-12,053.03% -31.52% -23.65%
CG Oncology -15,945.17%-19.37%-18.72%

Summary

CG Oncology beats Septerna on 10 of the 16 factors compared between the two stocks.

Get Septerna News Delivered to You Automatically

Sign up to receive the latest news and ratings for SEPN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SEPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SEPN vs. The Competition

MetricSepternaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$713.36M$3.16B$5.76B$10.50B
Dividend YieldN/A2.36%5.53%4.57%
P/E Ratio-1.5921.0475.9626.62
Price / Sales662.92252.06473.7891.77
Price / CashN/A46.3537.4661.85
Price / Book1.709.7813.486.45
Net Income-$71.80M-$52.73M$3.29B$271.57M
7 Day Performance11.61%3.16%1.83%2.61%
1 Month Performance33.94%4.69%4.00%7.28%
1 Year PerformanceN/A16.37%75.89%29.60%

Septerna Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SEPN
Septerna
1.4565 of 5 stars
$16.06
+0.4%
$26.75
+66.6%
N/A$713.36M$1.08M-1.59N/AAnalyst Upgrade
CGON
CG Oncology
2.5536 of 5 stars
$37.59
+1.5%
$56.00
+49.0%
-4.3%$2.87B$1.14M-21.3061Insider Trade
Gap Up
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
HCM
HUTCHMED
2.3816 of 5 stars
$16.27
-2.4%
$20.88
+28.3%
-3.1%$2.84B$630.20M0.001,811News Coverage
Analyst Downgrade
RARE
Ultragenyx Pharmaceutical
4.3856 of 5 stars
$29.13
-1.2%
$81.50
+179.8%
-50.7%$2.81B$560.23M-5.271,294Positive News
OGN
Organon & Co.
4.5663 of 5 stars
$10.68
+1.0%
$17.33
+62.4%
-46.4%$2.77B$6.40B3.964,000Positive News
ALVO
Alvotech
3.9816 of 5 stars
$8.91
+11.2%
$14.00
+57.1%
-20.0%$2.69B$491.98M38.811,032Trending News
Analyst Upgrade
Gap Up
High Trading Volume
KNSA
Kiniksa Pharmaceuticals International
2.6524 of 5 stars
$36.30
+0.6%
$41.17
+13.4%
+47.6%$2.69B$423.24M907.73220Positive News
IMVT
Immunovant
2.0234 of 5 stars
$15.43
-1.0%
$33.60
+117.8%
-47.4%$2.69BN/A-5.41120Positive News
GMTX
Gemini Therapeutics
N/A$61.50
+1.2%
N/A+27.8%$2.66BN/A-61.5030
MLYS
Mineralys Therapeutics
2.8353 of 5 stars
$38.29
-1.3%
$43.50
+13.6%
+228.8%$2.53BN/A-10.7228

Related Companies and Tools


This page (NASDAQ:SEPN) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners